BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

IMRIS Relase: Beijing PLA General Hospital Treats More Than 1,000 Neurosurgery Patients Using VISIUS® Surgical Theatre


11/15/2012 10:39:29 AM

iMRI assists in determining if all of tumor is removed

WINNIPEG, Nov. 15, 2012 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced PLA General Hospital in Beijing, China, has surpassed a major milestone of treating more than 1,000 neurosurgery patients using a VISIUS® Surgical Theatre. PLA General Hospital was the first hospital in China to install a VISIUS Surgical Theatre featuring a ceiling mounted, high-field intraoperative MR (iMRI) in February 2009.

"With the VISIUS Surgical Theatre, we recognized surgical precision enhancement and the ability to improve the extent of resection and reduce re-surgeries in tumor cases without moving the patient," said Dr. Bainian Xu, hospital chief neurosurgeon. "Use of iMRI," he said, "provided us the three M's of operation: maximum removal of lesion, minimum injury to neurologic function, and marvelous patient recovery."

Dr. Xu added, "The percentage of patients with total resection (tumor removal) in our department has been enhanced to 89%, and in 31% of all cases we resected additional tumor after an intraoperative MR scan that would have otherwise been missed." He also said this experience in improved precision is leading to fast developing changes in operational theories and methods for deep-brain, functional area and skull base procedures at their hospital.

The types of neurosurgical procedures included in the 1,000 cases are gliomas, pituitary adenomas, vascular lesions, frameless biopsies, skull-based procedures, metastatic tumor surgeries, epilepsy, and meningiomas.

This past April, Dr. Xiaolei Chen, associate professor of neurosurgery at PLA General Hospital, presented preliminary results of the first randomized clinical trial that studied the resection of low-grade insular glioma using high-field 1.5T iMRI at the American Association of Neurological Surgeons (AANS) annual meeting. The study results show significantly greater extent of tumor resection, better rates of total resection and better long-term outcomes for the group undergoing surgery with iMRI in a VISIUS Surgical Theatre, compared to the control group without iMRI.

About IMRIS

IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular and cerebrovascular markets and have been selected by leading medical institutions around the world.

   

 

 

SOURCE IMRIS Inc.


Read at BioSpace.com

IMRIS
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->